Children on semaglutide cut their body mass index (BMI, a ratio of weight to height) by 13.5% in the main analysis of the STEP Young trial. The figure is 17.4% if all children are assumed to have stayed on the drug until week 68. The two numbers come from different analyses and do not contradict each other. Placebo led to a 2.7% rise in the first and 2.2% in the second. The study was published on 16 November 2026 in the New England Journal of Medicine. It was funded by Novo Nordisk, which makes the drug.
The newsroom could not access the full text in the journal, so the figures were checked against several independent reviews of the paper and the company's statement.
167 children aged 6 to 11, split two to one
The trial included 167 children aged 6 to under 12 with obesity. Their average age was 10, and 59% were girls. More than 85% had severe obesity (class II or III). The children were assigned at random, two to one: 112 received weekly semaglutide injections and 55 received a placebo, an inactive injection. Both groups also got advice on eating fewer calories and moving more. The top dose was 1.7 mg or 2.4 mg, depending on weight.
Treatment lasted 104 weeks, followed by seven weeks without the drug. The main result was measured at week 68. Novo Nordisk's first statement, in September 2026, spoke of 165 children and only 68 weeks. The difference in numbers and time span comes from the different stages of publication.
BMI down 13.5% at week 68
A child's BMI is read against age and sex, so a 10% lower index is not the same as 10% less weight. Moving out of the "obesity" category also does not mean the child has reached a healthy weight. At week 68, BMI fell 13.5% with semaglutide and rose 2.7% with placebo, a gap of 16.2 percentage points. Some 38% of children on semaglutide fell below the obesity threshold, against 2% on placebo. And 79% moved to a lower BMI category, against 23%.
The analysis of children who kept to treatment shows a 17.4% fall against a 2.2% rise, a gap of 19.7 points, with 40.4% of children below the obesity threshold. These are additional results and were not adjusted for multiple comparisons. The authors of the review advise reading them with caution.
At week 104 the effect was smaller, but the gap with placebo remained: a 9.4% fall with semaglutide against an 8.4% rise with placebo, or 17.8 points. During the seven weeks off the drug, BMI in the semaglutide group began to rise again.
Stomach side effects and approval for teenagers
Side effects occurred in 96% of children on semaglutide and 93% of those on placebo. Most were stomach and bowel problems: vomiting in 70% against 29%, diarrhoea in 62% against 35%, and nausea in 58% against 24%. Some 4% of children on semaglutide and 2% on placebo stopped treatment. Serious events occurred in 9% of each group. The researchers saw no effect on puberty or bone density, but the longer-term effects on growth and development are unknown. The warning about the risk of thyroid tumours is part of the drug's general information and is not a result of this trial.
The US regulator, the FDA, approved the drug for teenagers aged 12 to 17 in December 2022, but not for younger children. Novo Nordisk's statement says the trial was run as a requirement after the drug went on sale. It gives no timeline for applying for the 6–11 age group. The American Academy of Pediatrics guidelines from 2023 allow drugs from age 8, alongside changes in habits. The WHO guidelines recommend drugs only for 10- and 11-year-olds, and only if lifestyle changes do not help. For children up to 9 they do not recommend them at all. The study's authors have ties to Novo Nordisk, and some also to Eli Lilly.
The researchers have promised data covering the 26 weeks after treatment stops.
Comments (1)
17,4 процента? Ехааа... Интересно ми е